Burning Rock Biotech Financials - Benzinga

Burning Rock Biotech Ltd

BNRNASDAQ

Trade with Public

Trade with Public

$10.05

-0.81-7.43%

At close: Aug 10, 5:00 PM EST

$10.64

-0.22-2%

Pre-Market: 4:00 AM EST

Overview News Earnings Forecast EventsFinancialsSentiment Ownership Compare Stock Report

Burning Rock Biotech Financials

Burning Rock Biotech (BNR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Earnings Scheduled For June 9, 2026

Benzinga Insights

PRO
Burning Rock Biotech Q1 EPS $(0.20), Same YoY, Sales $15.649M Down From $18.340M YoY

Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $15.649 million in sales this quarter. This is a 14.67 percent

Benzinga Newsdesk

PRO
Burning Rock Biotech Q4 EPS $(0.20) Up From $(1.10) YoY, Sales $18.063M Up From $17.265M YoY

Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is a 81.82 percent increase over losses of $(1.10) per share from the same period last year. The company reported $18.063 million in

Benzinga Newsdesk

Burning Rock Stock Up 35%+ As Loss Narrows

Bamboo Works

Earnings Scheduled For November 20, 2025

Benzinga Insights

PRO
Burning Rock Biotech Q3 EPS $(0.20) Up From $(0.50) YoY, Sales $18.488M Up From $18.331M YoY

Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is a 60 percent increase over losses of $(0.50) per share from the same period last year. The company reported $18.488 million in

Benzinga Newsdesk